156 related articles for article (PubMed ID: 22450313)
41. [Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
Zhou LL; Fu WJ; Yuan ZG; Wang DX; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):84-8. PubMed ID: 18315906
[TBL] [Abstract][Full Text] [Related]
42. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition.
Hu J; Dang N; Menu E; De Bruyne E; Xu D; Van Camp B; Van Valckenborgh E; Vanderkerken K
Blood; 2012 Jan; 119(3):826-37. PubMed ID: 22128141
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA; Nguyen AN; Hideshima T; Reddy M; Ma JY; Haghnazari E; Henson M; Stebbins EG; Kerr I; O'Young G; Kapoun AM; Chakravarty S; Mavunkel B; Perumattam J; Luedtke G; Dugar S; Medicherla S; Protter AA; Schreiner GF; Anderson KC; Higgins LS
Leukemia; 2006 Jun; 20(6):1017-27. PubMed ID: 16617327
[TBL] [Abstract][Full Text] [Related]
44. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
[TBL] [Abstract][Full Text] [Related]
45. [Molecular mechanism of myeloma cell line differentiation induced by 2-methoxyestradiol].
Gao WR; Hou J; Xiong H
Zhonghua Xue Ye Xue Za Zhi; 2005 Oct; 26(10):598-601. PubMed ID: 16532968
[TBL] [Abstract][Full Text] [Related]
46. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.
Gambella M; Rocci A; Passera R; Gay F; Omedè P; Crippa C; Corradini P; Romano A; Rossi D; Ladetto M; Boccadoro M; Palumbo A
Haematologica; 2014 Feb; 99(2):e14-6. PubMed ID: 24497562
[No Abstract] [Full Text] [Related]
47. Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib.
Nerini-Molteni S; Ferrarini M; Cozza S; Caligaris-Cappio F; Sitia R
Br J Haematol; 2008 May; 141(4):494-503. PubMed ID: 18341633
[TBL] [Abstract][Full Text] [Related]
48. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6.
Hongming H; Jian H
Leuk Res; 2009 Jan; 33(1):115-22. PubMed ID: 18778854
[TBL] [Abstract][Full Text] [Related]
49. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
[TBL] [Abstract][Full Text] [Related]
50. The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway.
Luo P; Lin M; Li L; Yang B; He Q
PLoS One; 2011; 6(11):e27298. PubMed ID: 22087283
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
[TBL] [Abstract][Full Text] [Related]
52. The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.
Eda H; Aoki K; Kato S; Okawa Y; Takada K; Tanaka T; Marumo K; Ohkawa K
Eur J Haematol; 2010 Jul; 85(1):68-75. PubMed ID: 20192985
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib upregulates [corrected] the osterix expression by osteoblasts in the myeloma microenvironment: Implications into osteoblast function in myeloma bone disease.
Terpos E
Leuk Res; 2010 Jun; 34(6):700-1. PubMed ID: 20074800
[No Abstract] [Full Text] [Related]
54. Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.
Stuhler G; Nekova TS
Blood; 2014 Jul; 124(4):657-8. PubMed ID: 25061173
[No Abstract] [Full Text] [Related]
55. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide).
Congdon LM; Pourpak A; Escalante AM; Dorr RT; Landowski TH
Biochem Pharmacol; 2008 Feb; 75(4):883-90. PubMed ID: 18062937
[TBL] [Abstract][Full Text] [Related]
56. Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma.
Mirandola L; Yu Y; Chui K; Jenkins MR; Cobos E; John CM; Chiriva-Internati M
PLoS One; 2011; 6(7):e21811. PubMed ID: 21765917
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.
Jaganathan S; Malek E; Vallabhapurapu S; Vallabhapurapu S; Driscoll JJ
Oncotarget; 2014 Dec; 5(23):12358-70. PubMed ID: 25481044
[TBL] [Abstract][Full Text] [Related]
58. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Bonomini S; Crugnola M; Mancini C; Martella E; Ferrari L; Tabilio A; Rizzoli V
Blood; 2007 Jul; 110(1):334-8. PubMed ID: 17371942
[TBL] [Abstract][Full Text] [Related]
59. Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.
Kikuchi J; Koyama D; Mukai HY; Furukawa Y
Int J Hematol; 2014 Jun; 99(6):726-36. PubMed ID: 24706190
[TBL] [Abstract][Full Text] [Related]
60. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.
Leung-Hagesteijn C; Erdmann N; Cheung G; Keats JJ; Stewart AK; Reece DE; Chung KC; Tiedemann RE
Cancer Cell; 2013 Sep; 24(3):289-304. PubMed ID: 24029229
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
